Imagion Biosystems is pleased to announce that it has successfully applied for an Advance/Overseas Finding in relation to its research and development activities for a new superparamagnetic based imaging technology for detection of HER2 breast cancers.
View the announcement.
The Stock Network Interview – Opening US trial sites for MagSense® breast cancer imaging
October 17, 2026
Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how MagSense® looks to improve upon today’s imaging, what the